Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$147.76 USD
-1.62 (-1.08%)
Updated May 24, 2024 04:00 PM ET
After-Market: $147.87 +0.11 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$147.76 USD
-1.62 (-1.08%)
Updated May 24, 2024 04:00 PM ET
After-Market: $147.87 +0.11 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Zacks News
Alnylam (ALNY) Q3 Loss Narrower than Expected, Revenues Rise
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.32 per share in the fourth quarter of 2016, narrower than both the Zacks Consensus Estimate loss of $1.35 and the year-ago loss of $1.07.
The Medicines Co LDL-Lowering Drug Positive in Phase II
by Zacks Equity Research
The Medicines Company (MDCO) announced positive top-line results from a Day 180 interim analysis of the ongoing ORION-1 phase II study on its pipeline candidate, Inclisiran (formerly PCSK9si), for the treatment of hypercholesterolemia.
Alnylam Reports Positive Data on Fitusiran, Givosiran
by Zacks Equity Research
Alnylam (ALNY) announced new positive data from an ongoing phase II OLE study on fitusiran for the treatment of patients with hemophilia A or B, without inhibitors.